Highest-materiality recent filing
Henry Schein elects William K. Daniel as Independent Chairman; Bergman retires
William K. Daniel elected Independent Chairman effective May 21, 2026.
Henry Schein Q1 GAAP EPS $0.92, non-GAAP $1.32; reaffirms 2026 guidance
Q1 GAAP diluted EPS $0.92 vs $0.88 YoY; non-GAAP diluted EPS $1.32 vs $1.15 YoY.
Henry Schein Q4 sales +7.7%, non-GAAP EPS $1.34; 2026 guide $5.23-$5.37
Q4 GAAP EPS $0.85 vs $0.74; non-GAAP EPS $1.34 vs $1.19; total sales $3.4B (+7.7% YoY, internal 4.9%).
Henry Schein names Frederick Lowery as CEO effective March 2, 2026; Bergman remains Chairman
Frederick Lowery (ex-Thermo Fisher EVP) succeeds Stanley Bergman as CEO; Bergman continues as Chairman.
Henry Schein Q3 2025 non-GAAP EPS $1.38 vs $1.22; raises FY guidance
Q3 GAAP EPS $0.84 vs $0.78; non-GAAP EPS $1.38 vs $1.22; revenue $3.3B up 5.2% YoY.
Henry Schein Q2 GAAP EPS $0.70 (down 12.5% YoY); maintains FY25 guidance
Q2 GAAP net income $86M ($0.70 diluted EPS) vs $104M ($0.80) YoY; non-GAAP EPS $1.10 vs $1.23.
Stanley M. Bergman to retire as Henry Schein CEO at end of 2025; will remain Chairman
Bergman to retire as CEO effective Dec 31, 2025, after 45 years at the company, over 35 as CEO.
Henry Schein closes $250M KKR investment; Dan Daniel joins board
KKR invested $250M for ~12% of HSIC common shares at ~$76.10/share in private placement.
Henry Schein Q1 GAAP EPS $0.88 (+22% YoY); non-GAAP EPS $1.15 (+4.5%); maintains FY guidance
Q1 net sales $3.2B; constant currency sales up 1.4% (2.0% ex-PPE/COVID test kits).
Henry Schein Q4 2024 non-GAAP EPS $1.19 vs $0.66; guides 2025 EPS $4.80-$4.94
Q4 revenue $3.2B (+5.8% YoY); non-GAAP diluted EPS $1.19 (prior year $0.66).
Henry Schein announces $250M KKR investment, preliminary Q4 EPS $1.19, and 2025 guidance
KKR to invest $250M at ~$76.10/share, becoming 12% common shareholder with board seats.
Henry Schein Q3 GAAP EPS $0.78, non-GAAP $1.22; raises FY2024 non-GAAP EPS guidance to $4.74-$4.82
Total net sales $3.2B, up 0.4% YoY; internal sales down 2.6% reflecting cyber incident recovery and lower PPE sales.
Henry Schein Q2 GAAP EPS $0.80 vs $1.06 YoY; lowers FY24 guidance, announces restructuring
Q2 total sales $3.1B (+1.1% YoY); internal sales down 2.4%.
Henry Schein Q1 sales $3.2B, GAAP EPS $0.72; tightens 2024 sales growth guidance to 8-10%
Q1 total sales $3.2B (+3.7% YoY); internal sales -1.8% due to cyber incident (300-400 bps drag) and lower glove pricing.
Henry Schein Q4 GAAP EPS $0.13, non-GAAP $0.66; guides 2024 EPS $5.00-$5.16
Q4 net sales $3.0B (-10.5% YoY); estimated $350M-$400M reduction from cybersecurity incident.
On May 16, 2025, William K. “Dan” Daniel was appointed to the Company’s board of directors (the “ Board ”) as a director.
On May 2, 2025, Max Lin was appointed to the Company’s board of directors (the “ Board ”) as a director.
On March 11, 2025, James P. Breslawski, President of Henry Schein, Inc. (the “Company”), informed the Company that effective as of April 1, 2025, he will transition out of the role of President of the Company.
On January 27, 2025, Robert J. Hombach was appointed to the Board as a director.
Max materiality 0.85 · Median 0.68 · Most common event earnings